| Role of cytoreductive radical prostatectomy in men with oligometastatic prostate cancer on molecular imaging D Robesti, A Gallina, F Montorsi, A Briganti, N Fossati Current Opinion in Urology 34 (4), 294-299, 2024 | | 2024 |
| The Impact of Second Opinion Expert Pathology Review in Patient Management at the Time of Transurethral Resection of the Bladder D Robesti, M Moschini, NP Tenace, G Burgio, C Re, R Leni, M De Angelis, ... European Urology Focus, 2024 | | 2024 |
| Hormonal agents in localized and advanced prostate cancer: current use and future perspectives. F Turco, C Buttigliero, MD Delcuratolo, S Gillessen, UM Vogl, T Zilli, ... Clinical Genitourinary Cancer, 102138, 2024 | | 2024 |
| Training and education in robotic surgery: Recommendations of ERUS (EAU robotic urology section) A Heinze, M Paciotti, N Fossati, A Mottrie Robotic Urology, 65-77, 2024 | | 2024 |
| MP71-07 THE IMPACT OF CENTRALIZED UROPATHOLOGY REVIEW IN THE MANAGEMENT OF BLADDER CANCER PATIENTS AT THE TIME OF TRANSURETHRAL RESECTION OF THE BLADDER D Robesti, M Moschini, NP Tenace, G Burgio, C Re, RI Leni, ... The Journal of Urology 211 (5S), e1163, 2024 | | 2024 |
| The impact of centralized uropathology review in the management of bladder cancer patients at the time of transurethral resection of the bladder D Robesti, M Moschini, NP Tenace, G Burgio, C Re, R Leni, M De Angelis, ... European Urology 85, S2125, 2024 | | 2024 |
| Survivorship data in Prostate Cancer: Where are we and where do we need to be? B Russell, K Beyer, A Lawlor, MJ Roobol, LDF Venderbos, S Remmers, ... European Urology Open Science 59, 27-29, 2024 | | 2024 |
| Management of patients with advanced prostate cancer—metastatic and/or castration-resistant prostate cancer: report of the Advanced Prostate Cancer Consensus Conference (APCCC … S Gillessen, A Bossi, ID Davis, J de Bono, K Fizazi, ND James, N Mottet, ... European journal of cancer 185, 178-215, 2023 | 58 | 2023 |
| PD39-10 THE ASSOCIATION BETWEEN PSA DENSITY AND THE DETECTION OF CLINICALLY SIGNIFICANT PROSTATE CANCER ACROSS ALL PIRADS SCORES IN MEN WITH POSITIVE MPMRI. WHEN PSA DENSITY … F Pellegrino, G Gandaglia, A Stabile, V Cucchiara, M Bandini, E Mazzone, ... The Journal of Urology 209 (Supplement 4), e1049, 2023 | | 2023 |
| MP40-07 HAS THE INTRODUCTION OF MULTIPARAMETRIC MAGNETIC RESONANCE IMAGING OF THE PROSTATE AND TARGETED BIOPSIES LED TO A RISK OF OVERGRADING OF HIGH RISK PROSTATE CANCER … G Sorce, A Stabile, G Gandaglia, V Cucchiara, E Mazzone, M Moschini, ... Journal of Urology 209 (Supplement 4), e547, 2023 | | 2023 |
| MP38-03 DOES PROSTATE CANCER FAMILY HISTORY HAVE AN IMPACT ON ACTIVE SURVEILLANCE ADHERENCE IN MEN WITH LOW-OR FAVOURABLE INTERMEDIATE RISK DISEASE? R Leni, A Stabile, G Gandaglia, V Cucchiara, M Bandini, E Mazzone, ... Journal of Urology 209 (Supplement 4), e524, 2023 | | 2023 |
| MP11-11 TAILORING THE OPTIMAL USE OF ANDROGEN-DEPRIVATION THERAPY CONCOMITANT TO POST-OPERATIVE RADIOTHERAPY AMONG MEN WITH PN1 PROSTATE CANCER. LONG-TERM RESULTS OF A LARGE … E Mazzone, G Gandaglia, F Barletta, A Necchi, D Raggi, L Marandino, ... The Journal of Urology 209 (Supplement 4), e128, 2023 | | 2023 |
| PD39-06 INTEGRATING INDEX LESION VOLUME TO BETTER CLASSIFY MEN WITH INDOLENT PROSTATE CANCER AMONG PATIENTS WITH INTERMEDIATE RISK DISEASE. RESULTS FROM A LARGE, MULTI … A Stabile, G Gandaglia, F Pellegrino, E Mazzone, V Cucchiara, N Fossati, ... Journal of Urology 209 (Supplement 4), e1047, 2023 | | 2023 |
| MP67-06 OUTCOMES OF PROSTATE CANCER PATIENTS WITH SEMINAL VESICLE INVASION AT MULTIPARAMETRIC MRI MANAGED WITH RADICAL PROSTATECTOMY. DO ALL PATIENTS REALLY NEED A MULTI-MODAL … F Barletta, G Gandaglia, G Ploussard, M Valerio, R Campi, A Minervini, ... Journal of Urology 209 (Supplement 4), e945, 2023 | | 2023 |
| PD39-04 MPMRI OF THE PROSTATE IN PATIENTS CARRYING A HIGH CLINICAL RISK OF PROSTATE CANCER DIAGNOSIS: IS THIS IMAGING TEST NECESSARY FOR DIAGNOSTIC PURPOSES IN THIS SUBSET OF … A Stabile, G Gandaglia, F Pellegrino, V Cucchiara, E Mazzone, N Fossati, ... Journal of Urology 209 (Supplement 4), e1045, 2023 | | 2023 |
| Management of patients with advanced prostate cancer. Part I: intermediate-/high-risk and locally advanced disease, biochemical relapse, and side effects of hormonal treatment … S Gillessen, A Bossi, ID Davis, J de Bono, K Fizazi, ND James, N Mottet, ... European urology 83 (3), 267-293, 2023 | 62 | 2023 |
| Assessing the impact of TURBT specimens review by a dedicated uropathologist on clinical decision making process: Results from a single tertiary referral center D Robesti, NP Tenace, C Re, R Leni, M De Angelis, G Gandaglia, ... European Urology 83, S1527-S1528, 2023 | | 2023 |
| Has the introduction of multiparametric magnetic resonance imaging of the prostate and targeted biopsies led to a risk of overgrading of high risk prostate cancer? Results from … G Sorce, G Gandaglia, A Stabile, V Cucchiara, E Mazzone, N Fossati, ... European Urology 83, S1789-S1790, 2023 | | 2023 |
| Identifying the optimal candidates for concomitant androgen-deprivation therapy among patients receiving metastasis-directed therapy for positive 68Ga-PSMA PET/CT for … E Mazzone, G Gandaglia, A Stabile, D Robesti, A Necchi, D Raggi, ... European Urology 83, S1623-S1624, 2023 | | 2023 |
| Tailoring the optimal use of androgen-deprivation therapy concomitant to post-operative radiotherapy among men with pN1 prostate cancer. Long-term results of a large, single … E Mazzone, G Gandaglia, A Stabile, D Robesti, A Necchi, G Cirulli, ... European Urology 83, S1615, 2023 | | 2023 |
Alberto BrigantiVita-Salute San Raffaele University, Milan, Italy在 hsr.it 的电子邮件经过验证
